<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04427956</url>
  </required_header>
  <id_info>
    <org_study_id>DNR2015/373</org_study_id>
    <nct_id>NCT04427956</nct_id>
  </id_info>
  <brief_title>Corneal Crosslinking Treatment Study</brief_title>
  <acronym>PRICS</acronym>
  <official_title>Prospective Randomised Interventional Corneal Crosslinking Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three different protocols for inducing corneal crosslinks in subjets with progressive
      keratoconus will be evaluated in this randomised clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Riboflavin does not penetrate the intact corneal epithelium. CXL is typically performed using
      the so-called &quot;Dresden protocol&quot;. The Dresden protocol states 30 minutes of UVA-radiation
      (3mW/cm2) but a 10 minute irradiation protocol (9mW/cm2) is frequently used. Both of the
      protocols involve mechanical removal of the epithelium over the central 8 mm of the corneal
      surface. The first days after treatment therefore involves some degree of pain, often
      intense, and the presence of a healing epithelial defect may be associated with development
      of infiltrates in the cornea. A number of approaches have been evaluated in order to promote
      riboflavin penetration through the intact epithelium, of which iontophoresis appears most
      promising. Keratoconic corneas are thin at the cone location and sometimes it is difficult to
      maintain the safety margin of 400 microns during corneal crosslinking. Instead of using
      isotonic standard riboflavin, a swelling effect of the cornea can be obtained by using
      hypotonic riboflavin. However, the latter has been indicated as less effective in the process
      of inducing cross links.

      Ninety eyes of 90 patients of various degrees of keratoconus will be randomised to one of the
      following groups: 1) CXL (UVA 9mW/cm2) using isotonic riboflavin, or 2) CXL (UVA 9mW/cm2)
      using hypotonic riboflavin or 3) Iontophoresis with Ricrolin with following CXL (UVA
      9mW/cm2).

      Hypothesis:

      i) CXL with hypotonic riboflavin or CXL with Ricrolin administered by iontophoresis or CXL
      with isotonic riboflavin is non-inferior compared to standard CXL with isotonic riboflavin.

      ii) The morphological structure post-CXL in the three different groups will be similar
      without any significant differences.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized interventional clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative change in visual acuity</measure>
    <time_frame>Patients will be evaluated 1, 6, 12 and 24 months after treatment.</time_frame>
    <description>Uncorrected visual acuity (UCVA) and best spectacle corrected visual acuity (BSCVA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative change in Kmax</measure>
    <time_frame>Patients will be evaluated 1, 6, 12 and 24 months after treatment.</time_frame>
    <description>Maximum corneal steepness</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative change in astigmatism</measure>
    <time_frame>Patients will be evaluated 1, 6, 12 and 24 months after treatment.</time_frame>
    <description>Corneal astigmatism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative change in corneal nerve cell density</measure>
    <time_frame>Confocal microscopy will be performed at 6 and 12 months.</time_frame>
    <description>Corneal nerve cell density will be evaluated using confocal microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative change in Keratocyte cell density</measure>
    <time_frame>Confocal microscopy will be performed at 6 and 12 months.</time_frame>
    <description>Keratocyte cell density will be evaluated using confocal microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative change in endothelial cell count</measure>
    <time_frame>Confocal microscopy will be performed at 6 and 12 months.</time_frame>
    <description>Endothelial cell count will be evaluated using confocal microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative change in demarcation lines</measure>
    <time_frame>Confocal microscopy will be performed at 6 and 12 months.</time_frame>
    <description>Identification of the demarcation lines with confocal microscopy will help establishing how deep was the effect of the CXL treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative change in the corneal thickness during CXL treatment</measure>
    <time_frame>Corneal pachymetry will be evaluated before and then every 5 minutes during 30 minutes under CXL treatment.</time_frame>
    <description>Corneal pachymetry is the process of measuring the thickness of the cornea</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Progressive Keratoconus</condition>
  <arm_group>
    <arm_group_label>Isotonic riboflavin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CXL (UVA 9mW/cm2) treatment using isotonic riboflavin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypotonic riboflavin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CXL (UVA 9mW/cm2) using hypotonic riboflavin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iontophoresis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iontophoresis with Ricrolin with following CXL (UVA 9mW/cm2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Corneal crosslinking: CXL (UVA 9mW/cm2)</intervention_name>
    <description>CXL treatment with UVA-radiation (9mW/cm2) with a 10 minute irradiation protocol.</description>
    <arm_group_label>Hypotonic riboflavin</arm_group_label>
    <arm_group_label>Iontophoresis</arm_group_label>
    <arm_group_label>Isotonic riboflavin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic riboflavin</intervention_name>
    <description>CXL protocol with isotonic riboflavin</description>
    <arm_group_label>Isotonic riboflavin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypotonic riboflavin</intervention_name>
    <description>CXL protocol with hypotonic riboflavin</description>
    <arm_group_label>Hypotonic riboflavin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Iontophoresis</intervention_name>
    <description>CXL protocol with iontophoresis and ricrolin</description>
    <arm_group_label>Iontophoresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Progress in keratoconic eye. We define progress as an increase in Kmax of 1.0 diopter
             in 1 year or 0.5 diopter in 6 months. This increase in Kmax will be accepted as
             progression if concomitant changes tomographic parameters.

        Exclusion Criteria:

          -  Concurrent ocular infection or corneal disease other than keratoconus.

          -  Pregnancy.

          -  Treatment with Isotretinoin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ingemar Gustafsson, M.D</last_name>
    <phone>004640332548</phone>
    <email>gustafsson.ingemar@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>André Vicente, M.D Ph.D</last_name>
    <phone>0046764082168</phone>
    <email>andre.vicente@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <state>Skåne</state>
        <zip>22242</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingemar Gustafsson, M.D</last_name>
      <phone>004640332548</phone>
      <email>gustafsson.ingemar@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>André Vicente, M.D. PhD</last_name>
      <phone>0046764082168</phone>
      <email>andre.vicente@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>corneal crosslinking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

